IL-33 Protein (AA 112-270)

Catalog No. ABIN1343984

This Recombinant IL-33 protein is produced in Escherichia coli (E. coli).

Quick Overview for IL-33 Protein (AA 112-270) (ABIN1343984)

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human, Mouse

Source: Escherichia coli (E. coli)

Application: SDS-PAGE (SDS)

Purity: >95 % (SDS-PAGE)

Product Details

Protein Characteristics: AA 112-270

Purpose: IL-33 (human) (rec.) (untagged)

Specificity: Binds to human ST2.

Cross-Reactivity: Human, Mouse

Characteristics: Human IL-33 (aa 112-270) is untagged.

Endotoxin Level: <0.01EU/μg purified protein (LAL test).

Biological Activity Comment: Activates human and mouse ST2-dependent NF-kappaB pathway.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Reconstitute with 100 μL sterile water.

Concentration: 0.1 mg/mL

Buffer: Contains PBS.

Handling Advice: After reconstitution, prepare aliquots and store at -20 °C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1 % BSA should be used for further dilutions.

Storage: 4 °C,-20 °C

Storage Comment:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.

Expiry Date: 6 months

Target Details

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Alternative Name: IL-33

Background:

Interleukin-33, IL-1F11, NF-HEV

Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1(MAPK3)/ERK2(MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.

Molecular Weight: ~18kDa

UniProt: Q2YEJ5

Pathways: Production of Molecular Mediator of Immune Response